Education + Advocacy = Change

Click a topic below for an index of articles:

New-Material

Home

Alternative-Treatments

Financial or Socio-Economic Issues

Forum

Health Insurance

Hepatitis

HIV/AIDS

Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

If you would like to submit an article to this website, email us at info@heart-intl.net for a review of this paper

any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”

    

 


 

Update from New Zealand’s Battle with Hepatitis C Virus

New funding offers hepatitis C patients chance for cure
04 February 2004 

Some New Zealand hepatitis C sufferers living with "a time bomb in
their livers" now have a better chance of being cured with the
Government's agreement to a more effective treatment.

From March 1, pegylated interferon in combination with ribavirin will
be available fully funded for sufferers of the most virulent form of
the disease, type 1.

The combination therapy has a permanent cure rate of 50 per cent for
people with type 1 hepatitis C - a considerable improvement on the
previous cure rate of 36 per cent with standard interferon
combination therapy.


    



Government drug-buying agency, Pharmac, estimates about 250 people
will be able to access the treatment every year, at a cost of up to
$5 million.

About half of the estimated 30,000 New Zealanders infected with
hepatitis C are genotype 1, but the majority are unaware they have
the disease, which can take years to produce symptoms.

Pharmac chief executive Wayne McNee said the deal with the
pharmaceutical company Roche Products was "a step forward" for
sufferers of hepatitis C.

"We will be targeting the treatment to the largest identifiable
group, which is also the hardest group to treat using the standard
therapy," he said in a statement.

"We also expect that improving treatment will have downstream
benefits in other areas of the health sector, such as reducing the
demand for liver transplants as a result of hepatitis C infection."

Pharmac was also looking at ways of making the new treatment even
more widely available, he said.

Hepatitis Foundation chief executive John Hornell, a long-time
campaigner for the treatment, said hepatitis infections had
reached "epidemic proportions" in New Zealand and yesterday's
announcement was "great news".

"Having the most effective therapy available means a cure has become
a realistic goal for more people," he said.

"Living with hepatitis C can be like having a time-bomb in your
liver."

Common symptoms included fatigue, feeling unwell and alcohol
intolerance.

Chronic infection can lead to advanced liver disease (cirrhosis),
liver failure and liver cancer.


    



Mr Hornell said he hoped that the treatment would be rolled out over
time to other hepatitis sufferers.

Such a move would save the health system millions down the track, he
said yesterday.

"We used to be streets ahead of Australia when it came to hepatitis C
control but Australia has funded this drug since November last year."

The treatment had serious side-effects and patients and their
families and their primary health givers would need on-going support,
he said.

 

 

 

Email: